Literature DB >> 20689853

Assessment of the quality of reporting in abstracts of randomized controlled trials published in five leading Chinese medical journals.

Yaolong Chen1, Jing Li, Changlin Ai, Yurong Duan, Ling Wang, Mingming Zhang, Sally Hopewell.   

Abstract

BACKGROUND: Clear, transparent and sufficiently detailed abstracts of randomized trials (RCTs), published in journal articles are important because readers will often base their initial assessment of a trial on such information. However, little is known about the quality of reporting in abstracts of RCTs published in medical journals in China.
METHODS: We identified RCTs abstracts from 5 five leading Chinese medical journals published between 1998 and 2007 and indexed in MEDLINE. We assessed the quality of reporting of these abstracts based on the Consolidated Standards of Reporting Trials (CONSORT) abstract checklist. We also sought to identify whether any differences exist in reporting between the Chinese and English language version of the same abstract.
RESULTS: We identified 332 RCT abstracts eligible for examination. Overall, the abstracts we examined reported 0-8 items as designated in the CONSORT checklist. On average, three items were reported per abstract. Details of the interventions (288/332; 87%), the number of participants randomized (216/332; 65%) and study objectives (109/332; 33%) were the top three items reported. Only two RCT abstracts reported details of trial registration, no abstracts reported the method of allocation concealment and only one mentioned specifically who was blinded. In terms of the proportion of RCT abstracts fulfilling a criterion, the absolute difference (percentage points) between the Chinese and English abstracts was 10% (ranging from 0 to 25%) on average, per item.
CONCLUSIONS: The quality of reporting in abstracts of RCTs published in Chinese medical journals needs to be improved. We hope that the introduction and endorsement of the CONSORT for Abstracts guidelines by journals reporting RCTs will lead to improvements in the quality of reporting.

Entities:  

Mesh:

Year:  2010        PMID: 20689853      PMCID: PMC2914031          DOI: 10.1371/journal.pone.0011926

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

There are more than 1200 biomedical journals in China [1], which publish thousands of randomized controlled trials (RCTs) each year. Clear, transparent, and sufficiently detailed abstracts of RCTs are more important particularly in China and other developing countries where researchers and health professionals often use an abstract to decide whether to seek more information about a trial; or may have access to the abstracts only [2]. Previous studies have attempted to assess the quality of reporting in abstracts of clinical studies [3] or to assess the quality of reporting in abstracts of RCTs published in English language journals [4]. The aim of our study is to assess the quality of reporting in abstracts of RCTs published in five leading Chinese medical journals using the recent CONSORT (Consolidated Standards of Reporting Trials) checklist for reporting abstracts of RCTs.

Materials and Methods

1. Selection of journals and sample of abstracts of RCTs

We selected five leading Chinese medical journals indexed in MEDLINE from 1998 to 2007 with top ranking impact factor (IF) in each field based on the “2007 data for Sci-tech Journal Citation Reports of China”(Table 1) and with both English and Chinese abstracts: the National Medical Journal of China, Chinese Journal of Internal Medicine, Chinese Journal of Obstetrics and Gynecology, Chinese Journal of Pediatrics, and the Chinese Journal of Surgery.
Table 1

Number of abstracts identified and included from five Chinese medical journals.

Name of journalImpact factorTotal citationsNumber of RCTsPercent (%)
Chinese Journal of Pediatrics1.3472909339.9%
Chinese Journal of Obstetrics and Gynecology1.12127195015.1%
National Medical Journal of China1.091379212136.5%
Chinese Journal of Internal Medicine0.90324096820.5%
Chinese Journal of Surgery0.96332226018%
Total332100%

Data of impact factor and total citations are from the China Journal Citation Reports (CJCR) in 2007.

Data of impact factor and total citations are from the China Journal Citation Reports (CJCR) in 2007. The CBM (Chinese Biomedical Database) disk database was searched using an extended version of the Cochrane Highly Sensitive Search Strategy [5] (Table 2) to identify RCTs (searched April, 2008) for Chinese abstracts in each of the five leading journals. Based on the citation of each RCT, we hand searched these five printed journals for the English abstracts. We included all publications reporting RCTs,which was defined as a trial where the allocation of participants to interventions was described by the words random, randomly, randomized, or randomization in all disease areas and all types of interventions, dealing with patients or volunteers.
Table 2

Search strategy to identify RCTs in five leading Chinese medical journals.

1 random$
2 randomized controlled trial/
3 randomized controlled trial$.pt.
4 double blind
5 double blind method/
6 single blind
7 single blind method/
8 triple blind
9 blind$
10 or/1–9
11 10/limit:animal
12 10 not 11)

2. Evaluation Method

We assessed the quality of reporting in abstracts of RCTs based on the CONSORT for Abstracts checklist [6]. Refined items from the CONSORT for Abstracts are presented in the Table 3. We assessed each item as “reported” or “not reported” according to whether the author reported all the contents listed in the refined items or not. We checked for any differences in reporting between the Chinese and English language version of the same abstract.
Table 3

Adapted CONSORT for Abstracts checklist items reported in the 332 journal abstracts of RCTs.

ItemsDescriptionRefined itemsNo. reported Chinese abstracts (n = 332) (%)No. reported English abstracts (n = 332) (%)
TitleIdentification of the study as randomized34 (10%)47 (14%)
Authors* Contact details for the corresponding author--
Trial designDescription of the trial design19 (6%)10 (3%)
Methods
ParticipantsEligibility criteria for participants and the settings where the data were collected9 (3%)7 (2%)
Eligibility criteria for participants148(45%)120 (36%)
Eligibility criteria for settings15(5%)13(4%)
InterventionsInterventions intended for each group288 (87%)310 (93%)
ObjectiveSpecific objective or hypothesis109 (33%)103 (31%)
OutcomeClearly defined primary outcome for this report005 (2%)
RandomizationHow participants were allocated to interventions00
Description of the method for assigning participants10(3%)1 (0%)
Description of allocation concealment00
Blinding (masking)Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment00
Description of whether or not using blinding49 (15%)48 (14.%)
Description of who were blinded01 (0%)
Results
Numbers randomizedNumber of participants randomized to each group216 (65%)214 (65%)
Recruitment* Trial status---
Numbers analyzedNumber of participants analyzed in each group50 (15%)42 (13%)
OutcomeFor the primary outcome, a result for each group and the estimated effect size and its precision00
Result for each group135 (41%)159(48%)
Estimated effect size of a result for each group9 (3%)4 (1%)
Precision of the estimate6 (2%)6 (2%)
HarmsImportant adverse events or side effects30 (9%)33 (10%)
ConclusionsGeneral interpretation of the results22 (7%)15 (5%)
Trial registrationRegistration number and name of trial register2 (1%)2 (1%)
FundingSource of funding86 (26%)86 (26%)

*Authors and Recruitment are most specific to conference abstracts, and were not included.

*Authors and Recruitment are most specific to conference abstracts, and were not included. We determined the number and proportion (%) of RCT abstracts that reported each of the CONSORT for Abstracts checklist items. Four assessors (YL Chen, CL Ai, L Wang and YR Duan) independently rated each RCT abstract and inter-rater agreement for each checklist item was determined using the Kappa statistic. Overall, this produced good agreement between the reviewers (0.7). Discrepancies were resolved by consensus and or discussed. Data analysis was carried out using Excel 2003, Epidata 3.02 and Stata version 9.0.

Results

1. Quality of reporting in Chinese abstracts

We identified 692 abstracts of RCTs during our initial search and subsequently determined that 332 pairs were eligible for analysis based on our criteria of findings being reported both Chinese and English (Figure 1). We have presented the results of our findings in Table 3. Overall only 10% (34/332) of the abstracts could be identified as an RCT based on the title. No abstracts mentioned the method of allocation concealment and, while 49 (15%) RCT abstracts reported on blinding, only one indentified who was blinded. Although 65 (20%) of the abstracts mentioned adverse events or side effects, less than 10% reported specific symptoms (n = 20) or rates (n = 26). Lastly, 246 (75%) abstracts did not report their sources of funding.
Figure 1

Identification of RCT abstracts from the Chinese Biomedical Database.

2. Comparison the quality of reporting between the Chinese with English abstracts

The results of the English language version of the same RCT abstracts are also presented in Table 3. In terms of the proportion of RCT abstracts fulfilling a criterion, the absolute difference (percentage points) between the Chinese and English abstracts was 10% (ranging from 0 to 25%) on average, per item. Some items such as details of the primary outcome, were only reported in the English version of the abstract. Some items were complementary between the Chinese and English abstracts, for example, some Chinese abstracts only reported the “numbers randomized” while their corresponding English abstracts only reported the “numbers analyzed”.

Discussion

1. General quality of reporting in abstracts and its possible reasons

Our study indicates that the quality of reporting in abstracts of RCTs published in these five leading Chinese medical journals is insufficient. Overall, the average number of reported items in each RCT abstract, based on the CONSORT for Abstracts checklist, was three. None of the abstracts adequately reported the key features of the trial design, including the method of generating the allocation sequence, concealment of the allocation, or the estimated effect size and its precision for the primary outcome. Less than half of the RCT abstracts reported the study as randomized in the title, the number of participants analysed, details of harms, trial registration and source of funding. Berwanger and colleagues [7] evaluated the quality of reporting in 227 abstracts describing RCTs published in the New England Journal of Medicine, JAMA, the BMJ and the Lancet in 2006. In their paper, the authors identified that details regarding methodological quality were also poorly reported as only one RCT abstract described the method of allocation concealment; 21 (9%) clearly specified who was blinded; 51 (23%) described intention-to-treat analysis; and 32 (14%) outlined losses to follow-up. In the mid-1990s, Anrong [8] and Bili [9] reported that the quality of abstracts in Chinese medical journals was poor. They suggested that poor abstract reporting may indicate suboptimal study design, inadequate reporting, or both. Previous work has shown that abstracts frequently under report key features of study design [10]–[11] and omit important results. It is suggested that the poor quality of reporting of Chinese abstracts may also be an indication of poor reporting in full-text RCTs in China [12]–[18]. When an item isn't reported in the full publication, it is likely to also be missing from the abstract. A lack of detailed requirement for abstracts in a journal's ‘Instruction for Authors’ is also a potential problem. Although most of the journals included in our study have adopted structured abstracts, the structured format alone is not sufficient to guide authors regarding their content. Thus, some of the most salient information might be missed if no detailed instructions for each heading are given. Finally, a lack of sufficient knowledge of research methodology might also attribute to the poor quality of reporting. Abstracts should contain the most important information and accurate study results relevant to clinical practice. While we did find that most abstracts reported the purported “study benefits,” we also observed that the primary outcome, the estimated effect size, and the precision and harms of the study were rarely reported. Cumulatively, this lack of information hampers readers in making clinical decisions [19]–[20] and presents clinicians many difficulties when trying to evaluate the benefits and harms of any intervention. Unfortunately, only two RCT abstracts reported details of trial registration. While, not included in our study, the Chinese Journal of Evidence-Based Medicine recently introduced the CONSORT for Abstracts guidelines into its ‘Instructions for Authors’ [21]. The application of the CONSORT Statement has demonstrated benefits in improving the quality of reporting in abstracts [22]–[24], and we hope that it will do the same with the introduction of CONSORT for Abstracts. We very much hope that the five journals included in our study will also consider including such guideline to their ‘Instructions for Authors’.

2. Limitations

This study has several limitations, firstly, we did not take a random sample of all RCT abstracts published in Chinese medical journals and therefore our findings may not reflect all abstracts of RCTs published in China or in other countries. Secondly, we did not compare abstracts with their corresponding full articles, However, previous studies have shown that the quality of reporting of the full-text is also poor in the same medical journals [12]–[18]. We further wish to point out that the WHO International Clinical Trial Register Platform only approved The Chinese Clinical Trial Register (ChiCTR) in 2007. Thus, it may well be that many researchers do not know the importance of prospective trial registration [25]. While not included in our current study, the Chinese Journal of Evidence-Based Medicine recently introduced the CONSORT for Abstracts guidelines into its ‘Instructions for Authors’ [21]. This adoption has improved the quality of reporting in other journals [22]–[24] and it is our sincere hope that the five journals included in our study, as well as other Chinese journals, adopt the CONSORT statement for Abstracts into their ‘Instructions for Authors.’ We believe that this adoption will markedly improve both the interpretation and practice of medicine in China in the future.

Conclusions

In summary, the quality of reporting in abstracts of RCTs published in these five leading Chinese medical journals requires substantial improvement to meet the recommendations set out in CONSORT for Abstracts guidelines. With the publication of CONSORT for Abstracts checklist, we suggest that Chinese medical journals should adopt these recommendations and do more to ensure that authors apply to meet internationally agreed standards, thereby allowing the conduct of their studies to be monitored and improved.
  14 in total

1.  Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed.

Authors:  Karen A Robinson; Kay Dickersin
Journal:  Int J Epidemiol       Date:  2002-02       Impact factor: 7.196

2.  Quality of abstracts in 3 clinical dermatology journals.

Authors:  Alain Dupuy; Kiarash Khosrotehrani; Celeste Lebbé; Michel Rybojad; Patrice Morel
Journal:  Arch Dermatol       Date:  2003-05

3.  Abstract reporting in randomized clinical trials of acute lung injury: an audit and assessment of a quality of reporting score.

Authors:  Karen E A Burns; Neill K J Adhikari; Michelle Kho; Maureen O Meade; Rakesh V Patel; Tasnim Sinuff; Deborah J Cook
Journal:  Crit Care Med       Date:  2005-09       Impact factor: 7.598

4.  For randomized controlled trials, the quality of reports of complementary and alternative medicine was as good as reports of conventional medicine.

Authors:  Terry P Klassen; Ba' Pham; Margaret L Lawson; David Moher
Journal:  J Clin Epidemiol       Date:  2005-08       Impact factor: 6.437

Review 5.  The quality of reporting of randomized controlled trials of traditional Chinese medicine: a survey of 13 randomly selected journals from mainland China.

Authors:  Gang Wang; Bing Mao; Ze-Yu Xiong; Tao Fan; Xiao-Dong Chen; Lei Wang; Guan-Jian Liu; Jia Liu; Jia Guo; Jing Chang; Tai-Xiang Wu; Ting-Qian Li
Journal:  Clin Ther       Date:  2007-07       Impact factor: 3.393

6.  Family physicians' use of medical abstracts to guide decision making: style or substance?

Authors:  H C Barry; M H Ebell; A F Shaughnessy; D C Slawson; F Nietzke
Journal:  J Am Board Fam Pract       Date:  2001 Nov-Dec

7.  Chinese authors do need CONSORT: reporting quality assessment for five leading Chinese medical journals.

Authors:  Lin Xu; Jing Li; Mingming Zhang; Changlin Ai; Ling Wang
Journal:  Contemp Clin Trials       Date:  2008-05-18       Impact factor: 2.226

8.  The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement.

Authors:  Edward J Mills; Ping Wu; Joel Gagnier; P J Devereaux
Journal:  Contemp Clin Trials       Date:  2005-03-31       Impact factor: 2.226

9.  CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration.

Authors:  Sally Hopewell; Mike Clarke; David Moher; Elizabeth Wager; Philippa Middleton; Douglas G Altman; Kenneth F Schulz
Journal:  PLoS Med       Date:  2008-01-22       Impact factor: 11.069

10.  An assessment of the quality of randomised controlled trials conducted in China.

Authors:  Dalu Zhang; Peng Yin; Nick Freemantle; Rachel Jordan; Nanshan Zhong; K K Cheng
Journal:  Trials       Date:  2008-04-24       Impact factor: 2.279

View more
  21 in total

Review 1.  Barriers to translating EU and US CVD guidelines into practice in China.

Authors:  Dong Zhao; Dayi Hu
Journal:  Nat Rev Cardiol       Date:  2012-05-01       Impact factor: 32.419

2.  Pharmacy journal abstracts published in PubMed that abide by the CONsolidated Standards Of Reporting Trials (CONSORT) guidelines.

Authors:  Daniel A Blair; Peter J Hughes; Thomas W Woolley
Journal:  J Med Libr Assoc       Date:  2014-04

3.  Forty-five years of schizophrenia trials in Italy: a survey.

Authors:  Marianna Purgato; Clive Adams; Corrado Barbui
Journal:  Trials       Date:  2012-04-12       Impact factor: 2.279

Review 4.  Characteristics of randomized trials published in Latin America and the Caribbean according to funding source.

Authors:  Ludovic Reveiz; Stephanie Sangalang; Demian Glujovsky; Carlos E Pinzon; Claudia Asenjo Lobos; Marcela Cortes; Martin Cañón; Ariel Bardach; Xavier Bonfill
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

5.  Schizophrenia trials conducted in African countries: a drop of evidence in the ocean of morbidity?

Authors:  Marianna Purgato; Clive Adams; Corrado Barbui
Journal:  Int J Ment Health Syst       Date:  2012-07-06

6.  Reporting characteristics of cancer pain: a systematic review and quantitative analysis of research publications in palliative care journals.

Authors:  Senthil P Kumar
Journal:  Indian J Palliat Care       Date:  2011-01

7.  Effect of editors' implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis.

Authors:  Sally Hopewell; Philippe Ravaud; Gabriel Baron; Isabelle Boutron
Journal:  BMJ       Date:  2012-06-22

Review 8.  A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.

Authors:  Ying Zhang; Thomas Becker; Yongchun Ma; Markus Koesters
Journal:  BMC Psychiatry       Date:  2014-08-27       Impact factor: 3.630

Review 9.  Aminophylline for bradyasystolic cardiac arrest in adults.

Authors:  Katrina F Hurley; Kirk Magee; Robert Green
Journal:  Cochrane Database Syst Rev       Date:  2015-11-23

Review 10.  Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.

Authors:  Shanthi Sivendran; Kristina Newport; Michael Horst; Adam Albert; Matthew D Galsky
Journal:  Trials       Date:  2015-08-08       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.